Our Best Stocks to Buy List: New Top Picks in Bioscience, Energy, and More

Email
    Text size

Best stocks to buy for the week ending July 4, 2014: Each week our experts dish out the latest profit plays and asset-protection moves for our Money Morning Members - all for free.

Last week, we covered a "catalyst" that could spark a share-price rally for what is already one of the best stocks to buy, three recommendations to take advantage of rising oil prices, how to cash in on the liquefied natural gas (LNG) boom, and a way to tap into big profits in an "other" bioscience niche that is less risky but highly lucrative.

Get these, plus the top healthcare picks, dividend stocks, and more, in the full list of our best stocks to buy now.

Add These Picks to Your "Stocks to Buy" List

  • With just six months left on Money Morning Bioscience Investment Specialist Ernie Tremblay's 2014 "profit calendar," things look very promising for bioscience investing in the second half of the year. For instance, the biologics subsector (compounds created naturally by living organisms and used as a different form of drugs) is growing fast. By 2016, biologics are predicted to account for 24% of sales in the world market - double their sales in 2004. And that's not the only market with strong growth this year. "The bioscience sector is healthy and full of potential for investors right now," Tremblay said - and he backed it up with tips for investors on how take advantage today of this sector's best opportunities...
  • Putting your money behind new, experimental drugs without some guidance can be a crapshoot. But there's an approach to this type of investing that doesn't rely on breakthrough discoveries, expensive drug trials, or constant, dilutive cash infusions: invest in generics. Generics hold a huge advantage in the marketplace. According to Forbes, the average new drug costs $4 billion to develop, the price tag can run as high as $11 billion, and it can take 10 to 15 years of trials before the drug hits the market. Generic manufacturers get to skip this altogether - once they prove they've got a good copy, they just make them and sell them. The challenge is finding a generics maker that has established a strong track record, but still has room to grow. Tremblay did just that and found a stock with a product portfolio that includes around 25 compounds, with 19 more pending with the FDA right now....
  • The European Union's (EU) recently unveiled Energy Master Plan talks about energy in the year 2030, but what really worries the EU is much more immediate - the coming winter. The ongoing civil war in eastern Ukraine means that Russian gas supplies could once again be cut off come September. And the last time Russia refused European natural gas deliveries, in 2009, the continent barely survived one of the coldest winters in years. Money Morning Global Energy Strategist Dr. Kent Moors thinks that this time around, Europe's savior could be the United States - which is good news for these natural gas stocks...
  • Moors appeared on CNBC's "Closing Bell" program July 1 to discuss his outlook for the strife in Iraq and what it will mean for oil prices. "I think the situation in Iraq is about to deleverage, and deleverage quickly," Moors stated. Even so, Moors said that certain oil companies were actually benefiting from the recent turbulence in crude oil prices. He talks about why this is happening - and provides three stock picks...